Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-683-1880
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees13
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable
Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions
What is Agile Therapeutics' stock symbol?
Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."
How were Agile Therapeutics' earnings last quarter?
Agile Therapeutics Inc (NASDAQ:AGRX) posted its quarterly earnings data on Monday, October, 28th. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.00. View Agile Therapeutics' Earnings History.
When is Agile Therapeutics' next earnings date?
What price target have analysts set for AGRX?
6 equities research analysts have issued 1 year price targets for Agile Therapeutics' stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate Agile Therapeutics' stock price to reach $4.20 in the next year. This suggests a possible upside of 200.0% from the stock's current price. View Analyst Price Targets for Agile Therapeutics.
What is the consensus analysts' recommendation for Agile Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics.
What are Wall Street analysts saying about Agile Therapeutics stock?
Here are some recent quotes from research analysts about Agile Therapeutics stock:
- 1. According to Zacks Investment Research, "Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. " (10/30/2019)
- 2. Maxim Group analysts commented, "Agile Therapeutics announced that the NDA for Twirla (low-dose contraceptive patch) has been resubmitted to the FDA. FDA has 30 days to accept; review period expected to be 6 months." (5/17/2019)
- 3. HC Wainwright analysts commented, "We don’t think this should even be required, as Twirla is a different product than Xulane/Ortho Evra, not a generic copy, so its benefit-risk profile—which we think is better—should stand on its own merits. Nevertheless, the minutes were consistent with our expectation for a straightforward two-week crossover study (one week on each patch) to show that Twirla adhesion is non-inferior (NI) to Xulane. The company has not disclosed the specific NI margin that the agency is requiring, but the planned sample size of only n=80 suggests to us that the FDA has given them some NI breathing room. We are confident in success based on Phase 3 adhesion data (more below). Agile already had the study teed up and ready to go, and has immediately initiated it with a dermatology-specialized CRO, TKL Research." (1/11/2019)
Has Agile Therapeutics been receiving favorable news coverage?
Media coverage about AGRX stock has trended very negative recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Agile Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Agile Therapeutics.
Who are some of Agile Therapeutics' key competitors?
Some companies that are related to Agile Therapeutics include BioDelivery Sciences International (BDSI), Retrophin (RTRX), Myovant Sciences (MYOV), Advanz Pharma (CXRXF), Urogen Pharma (URGN), XBiotech (XBIT), Aprea Therapeutics (APRE), Akorn (AKRX), Kadmon (KDMN), ChemoCentryx (CCXI), Progenics Pharmaceuticals (PGNX), Synthorx (THOR), ImmunoGen (IMGN), Dynavax Technologies (DVAX) and Intra-Cellular Therapies (ITCI).
What other stocks do shareholders of Agile Therapeutics own?
Who are Agile Therapeutics' key executives?
Agile Therapeutics' management team includes the folowing people:
- Mr. Alfred F. Altomari, Chairman & CEO (Age 60)
- Mr. Scott M. Coiante, CFO & Sr. VP (Age 52)
- Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 51)
- Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 53)
- Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 62)
How do I buy shares of Agile Therapeutics?
Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Agile Therapeutics' stock price today?
One share of AGRX stock can currently be purchased for approximately $1.40.
How big of a company is Agile Therapeutics?
Agile Therapeutics has a market capitalization of $83.02 million. The specialty pharmaceutical company earns $-19,780,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Agile Therapeutics employs 13 workers across the globe.View Additional Information About Agile Therapeutics.
What is Agile Therapeutics' official website?
How can I contact Agile Therapeutics?
Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected]
MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)
MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
